Restoration of this TH1 immune response with neoadjuvant HER2 peptide-pulsed type I DC (HER2-DC1) vaccination resulted in pathologic complete response in 30% of HER2+ DCIS patients in a randomized trial (161). Here, ERBB2 is linked to ductal breast carcinoma in situ.